ICIs selectively restore and normalize the body’s antitumor immune responses by disrupting the immunoinhibitory signals mediated by the PD-1/PD-L1 and CTLA-4 axes in the tumor microenvironment (1). The gene discussed is PDCD1; the disease is neoplasm.